Bayer (FRA:BAYN) has been given a €95.00 ($117.28) target price by equities researchers at Barclays in a research note issued to investors on Monday. The brokerage currently has a “sell” rating on the healthcare company’s stock. Barclays’ price objective would indicate a potential downside of 2.98% from the company’s previous close.
A number of other equities research analysts also recently commented on the company. Goldman Sachs Group set a €125.00 ($154.32) target price on Bayer and gave the company a “buy” rating in a research report on Tuesday, March 6th. Kepler Capital Markets set a €104.00 ($128.40) target price on Bayer and gave the company a “neutral” rating in a research report on Monday, March 5th. DZ Bank restated a “buy” rating on shares of Bayer in a research report on Friday, March 2nd. Cfra set a €105.00 ($129.63) target price on Bayer and gave the company a “buy” rating in a research report on Friday, March 2nd. Finally, Independent Research set a €102.00 ($125.93) price objective on Bayer and gave the company a “neutral” rating in a report on Thursday, March 1st. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of €119.41 ($147.42).
Shares of Bayer (FRA:BAYN) opened at €97.92 ($120.89) on Monday. Bayer has a 1 year low of €91.58 ($113.06) and a 1 year high of €123.82 ($152.86). The company has a market capitalization of $81,380.00 and a price-to-earnings ratio of 26.32.
TRADEMARK VIOLATION NOTICE: This story was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://sportsperspectives.com/2018/03/12/bayer-bayn-given-a-95-00-price-target-at-barclays.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.